Market Overview
Size, clinical scope, and hardware mix
- Brevintel analysis values the smart pills market at USD 1.3 billion in 2025 ($1.3B) and projects USD 3.9 billion by 2035 ($3.9B).
- The narrative path uses an 11.8% CAGR from 2026 to 2035, while headline cards list 12.3%; both token sets are retained.
- Medtronic led with over 41.2% share in 2025; Medtronic, CapsoVision, and Olympus Corporation collectively held 55%.
- Coverage includes ingestible systems for gastrointestinal imaging, site-specific drug delivery, medication-ingestion verification, and physiological monitoring, plus software that receives and interprets transmitted data.
- Capsule endoscopy remains the commercial center because it visualizes the small bowel, which conventional upper endoscopy and colonoscopy cannot examine completely.
- Published estimates put prevalent digestive-disease cases at 2.86 billion worldwide in 2019, while inflammatory bowel disease incidence rose substantially between 1990 and 2021.
- Product accounted for 63.2% of the market and USD 802.8 million in 2025, expanding at an 11.6% CAGR.
- Capsules represented 82.6% of product revenue and are projected to grow at 11.9% CAGR as providers select platforms on image coverage, battery performance, transmission, and indication.
Connected platforms and reading economics
- Brevintel analysis sees expansion as a shift from single-use diagnostic hardware toward connected clinical platforms that turn image streams and sensor signals into faster decisions.
- The USD 1.3 billion market in 2025 is anchored in established capsule-endoscopy workflows, but the path to USD 3.9 billion by 2035 depends on converting capture into clinically usable output.
- AI-assisted reading changes adoption economics by increasing the number of cases a gastroenterology team can process without a proportional increase in physician review capacity.
- Patient monitoring software, at 12.3% CAGR versus 11.6% for products, offers a route to improve installed-base economics through lower reading burden and recurring revenue.
- Small-bowel applications retain the deepest evidence base, whereas stomach and colon uses must show that navigation, preparation burden, diagnostic performance, and reimbursement fit the care setting.
- Magnetically controlled capsules support gastric visualization without sedation, ingestible sensors can verify medication ingestion, and wireless capsules can capture physiological signals from within the gastrointestinal tract.
- In a prospective multicenter study, AI-assisted reading was non-inferior to standard reading for suspected small-bowel bleeding and improved detection of clinically relevant lesions.
- Developers that pair a differentiated capsule with interoperable software and evidence for a defined clinical pathway are better positioned than suppliers offering hardware differentiation alone.
Market Dynamics
Demand drivers
- Global inflammatory bowel disease prevalence exceeded 3.83 million people in 2021, and incident cases rose to 375,140 that year, expanding the addressable population for noninvasive gastrointestinal assessment.
- For suspected Crohn's disease and obscure gastrointestinal bleeding, capsule endoscopy visualizes small-bowel mucosa without invasive endoscope advancement.
- Colon capsule endoscopy is relevant for patients who decline, cannot complete, or are unsuitable for conventional colonoscopy, creating a procurement case based on screening access rather than simple substitution.
- In a FIT-positive screening population, offering a choice between colon capsule endoscopy and colonoscopy improved participation, although downstream colonoscopy remains necessary when intervention or confirmation is required.
- Current platforms combine improvements in resolution, field of view, battery life, and frame rate with software designed to reduce repetitive image review.
- CapsoVision's lateral-view capsule architecture has been associated with more complete small-bowel examinations and greater visualization of selected anatomical landmarks than axial-view systems.
- ANX Robotica received FDA clearance for expanded NaviCam small-bowel indications, including pediatric use, alongside clearance for its ProScan AI-assisted reading software in January 2024.
- etectRx's FDA-cleared ID-Cap system records ingestion events through a sensor activated in gastric fluid, while Otsuka's Abilify MyCite established an earlier regulated model for recording aripiprazole ingestion.
Regulatory, cost, and supply constraints
- Smart pills can fall into medical-device, software-as-a-medical-device, or drug-device combination categories, so evidence burden rises with diagnostic, treatment, or adherence claims.
- ANX Robotica's De Novo authorization for magnetically controlled stomach capsule endoscopy created a regulatory precedent, while later clearances still require product-specific evidence as indications and software functions expand.
- European market access requires Medical Device Regulation compliance, including clinical evaluation and post-market obligations, as illustrated by Check-Cap's MDR CE Mark renewal for C-Scan.
- Providers may need recorders, reading workstations, software licenses, cybersecurity controls, trained personnel, and protocols for incomplete studies or findings that require conventional endoscopy.
- Medtronic discontinued its SmartPill GI Monitoring System in 2023 after being unable to secure alternative sources for specialized components.
- Reimbursement remains uneven by indication and geography; mature systems can support routine small-bowel capsule use, whereas colon screening, physiological monitoring, and therapeutic delivery may need further evidence.
- Brevintel analysis indicates the principal restraint is the interaction between regulation and service economics, not a lack of technical novelty.
- Hardware suppliers without a credible clinical-software strategy risk competing primarily on capsule price in a market where service workflows increasingly determine value.
Segmentation Analysis
Component
- Product accounted for 63.2% of the market and USD 802.8 million in 2025, expanding at an 11.6% CAGR as imaging and sensing hardware remain central to clinical procurement.
- Capsules represented 82.6% of product revenue and are projected to grow at 11.9% CAGR, reflecting selection on image coverage, battery performance, transmission method, and approved indication.
- Other products, including sensor belts and related tools, represented 17.4% of product-segment revenue and are projected to grow at 11.5% CAGR.
- Accessory growth is comparatively slower because connectivity and software integration can reduce the amount of dedicated external hardware required per procedure.
- Patient monitoring software accounted for 36.8% of revenue in 2025 and is projected to grow at 12.3% CAGR.
- AI triage, cloud data handling, case-management tools, and clinical-record integration make capsule systems more useful where specialist capacity is limited.
- Software determines whether higher image-capture rates translate into clinically manageable case volumes rather than simply adding recurring revenue.
- Brevintel analysis sees component mix shifting toward software that standardizes reading while capsules remain the hardware core of purchasing decisions.
Target area
- The stomach held 44% of revenue in 2025 and is projected to grow at 12% CAGR, reflecting magnetically controlled capsules for gastric visualization without sedation.
- Stomach adoption depends on consistent navigation quality and on whether local screening pathways treat capsule examination as complementary to conventional gastroscopy.
- The small intestine represented 26.7% of revenue, or USD 343.4 million, in 2025 and is projected to expand at 12.2% CAGR.
- Small-intestine use is the most established capsule-endoscopy case because the small bowel is difficult to reach with conventional endoscopy and has the deepest clinical evidence base.
- Improved completion rates strengthen the operational case, but transit variability and the absence of therapeutic capability remain important limitations.
- The large intestine accounted for 20.1% of revenue and is projected to grow at 12.4% CAGR, the fastest rate among target areas.
- Large-intestine growth is tied to screening access for patients unwilling or unable to undergo colonoscopy, especially when AI reduces reading effort and follow-up colonoscopy pathways are clear.
- The esophagus represented approximately 9.0% of revenue and is projected to grow at 11.7% CAGR, limited by the availability and procedural familiarity of upper endoscopy.
Application
- Capsule endoscopy generated 68.3% of application revenue in 2025 and is projected to grow at 11.6% CAGR, supported by clinical guidelines in defined small-bowel indications.
- The application remains dependent on specialist interpretation, which explains the strategic importance of AI-enabled review tools.
- Targeted drug delivery accounted for 20.5% of revenue and is projected to grow at 12.3% CAGR as research focuses on molecules that face absorption barriers through conventional oral administration.
- A 2024 Nature study demonstrated cephalopod-inspired ingestible jetting devices capable of delivering biologic payloads into gastrointestinal tissue, including insulin, a GLP-1 analogue, and siRNA.
- Commercial translation of targeted delivery will require reliable dosing, manufacturability, and combination-product regulatory evidence.
- Vital-sign monitoring represented approximately 11.2% of application revenue and is projected to grow at 11.6% CAGR.
- Bodycap's e-Celsius platform illustrates ingestible temperature capsules, while first-in-human research has shown a wireless ingestible pill can measure heart and respiratory rates in a sleep-apnea setting.
- These monitoring uses can serve high-value cohorts, but they require cases where internal physiological data improves decisions beyond wearable or external monitoring.
End use
- Hospitals held 61.6% of end-use revenue in 2025 and are projected to reach USD 2.4 billion by 2035 at a 12.0% CAGR.
- Hospital dominance follows from gastroenterologist concentration, imaging infrastructure, multidisciplinary follow-up, and high procedure volumes, including cases that escalate to therapeutic endoscopy or surgery.
- Diagnostic centers represented 34.2% of revenue and are projected to grow at 12.3% CAGR on standardized outpatient workflows, recorder logistics, data transfer, and software that reduces reading time.
- Centers that can coordinate referral and follow-up may capture lower-acuity diagnostic cases that do not require a hospital-based pathway.
- Other end users, including clinics and academic or research institutes, held 4.2% of revenue and are projected to grow at 11.7% CAGR.
- These settings are important for validating emerging capsule applications, though purchasing capacity is generally lower than that of hospitals and dedicated diagnostic networks.
- Brevintel analysis finds large-intestine applications, growing at 12.4% CAGR, can gain momentum where health systems recover screening participation among patients who do not complete colonoscopy.
- Parallel 12.3% CAGRs in patient monitoring software and diagnostic centers indicate that decentralized adoption will rely on software that concentrates specialist attention on clinically important findings.
Regional Outlook
North America and Europe
- North America accounted for 39.7% of global revenue and USD 503.5 million in 2025, with projected growth of 11.5% CAGR.
- The U.S. market reached USD 462 million in 2025, following growth from USD 343.8 million in 2022, USD 379.1 million in 2023, and USD 418.3 million in 2024.
- U.S. scale reflects established specialty care, high diagnostic procedure volumes, and major platform suppliers, with FDA clearances providing a comparatively well-defined path for many diagnostic capsule platforms.
- The withdrawal of Medtronic's SmartPill created a gap in wireless motility testing, showing that market maturity does not guarantee continuity of supply.
- Canada's opportunity is more dependent on provincial procurement and referral pathways, which can create variation in access across the country.
- Europe represented 28.6% of global revenue in 2025 and is projected to grow at 12.0% CAGR.
- Germany, the UK, France, Spain, Italy, and the Netherlands are the principal European markets; the UK's experience with colon capsule endoscopy in FIT-positive screening shows how organized pathways can create structured demand.
- EU MDR compliance raises development and maintenance costs, and reimbursement depth remains uneven, leaving adoption in some Southern European markets concentrated in larger hospitals and private networks.
Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific accounted for 22.3% of global revenue and USD 290 million in 2025 and is projected to grow at 12.3% CAGR.
- Japan combines established capsule-endoscopy reimbursement with clinical guidance that supports use in defined indications, making it attractive for incremental performance or workflow benefit.
- China, India, Australia, and South Korea offer different combinations of regulatory requirements, provider infrastructure, manufacturing capacity, and payer access.
- Latin America held 6.0% of revenue in 2025 and is projected to expand at 11.8% CAGR, with Brazil, Mexico, and Argentina forming the regional scope.
- Latin American adoption is concentrated in metropolitan private hospitals and specialist centers; reimbursement limitations and uneven specialist availability constrain broader public-sector penetration.
- Middle East & Africa accounted for 3.4% of global revenue in 2025 and is projected to grow at 11.3% CAGR, with South Africa, Saudi Arabia, and the UAE in scope.
- MEA demand is centered on tertiary hospitals, private healthcare groups, and medical-tourism hubs that can support specialist interpretation and follow-up procedures.
- Brevintel analysis sees North America retaining the largest revenue base, while Asia Pacific's 12.3% CAGR reflects Japan's mature reimbursement framework and expansion across larger, less penetrated healthcare markets.
Competitive Landscape
Structure and platform differentiation
- The market is moderately concentrated. Medtronic, Intromedic, and CapsoVision held more than 55% of global revenue in 2025, with Medtronic accounting for approximately 41.2%.
- Scale matters in established capsule endoscopy because clinical adoption depends on installed-base support, distribution, training, reimbursement engagement, and software updates.
- ANX Robotica develops the NaviCam magnetically controlled capsule platform; FDA-cleared NaviCam SB and ProScan AI reading software position the company in stomach and small-bowel workflows.
- CapsoVision markets CapsoCam Plus, which uses a 360-degree lateral-view design, with FDA 510(k) clearance for CapsoCam Plus SV-3 supporting its U.S. presence.
- Intromedic offers the MiroCam system, whose Human Body Communication transmission architecture differentiates the platform from conventional radiofrequency-based systems.
- Medtronic leads through its PillCam portfolio and broad distribution, although the 2023 SmartPill discontinuation illustrates limits of portfolio breadth when specialized component supply is disrupted.
- Olympus Corporation participates through the ENDOCAPSULE platform, combining a wide-angle capsule with a reading workstation and software features intended to reduce redundant image review.
- Check-Cap is developing C-Scan, an ultra-low-dose X-ray capsule intended for colorectal cancer screening without conventional bowel preparation or sedation.
Integrated producers
- Medtronic
- Olympus Corporation
- Otsuka Holdings
Specialty suppliers
- CapsoVision
- Intromedic
- ANX Robotica
- Bodycap
- Check-Cap
- etectRx
- RF Co., Ltd.